Log in

NASDAQ:IDXG - Interpace Diagnostics Group Stock Price, Forecast & News

$10.10
-0.45 (-4.27 %)
(As of 02/25/2020 01:15 AM ET)
Today's Range
$9.77
Now: $10.10
$10.50
50-Day Range
$0.56
MA: $6.96
$10.60
52-Week Range
$3.81
Now: $10.10
$11.00
Volume53,400 shs
Average Volume84,160 shs
Market Capitalization$38.58 million
P/E RatioN/A
Dividend YieldN/A
Beta2.04
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:IDXG
CUSIP69329V10
Phone855-776-6419

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$21.90 million
Book Value$11.48 per share

Profitability

Net Income$-12,190,000.00

Miscellaneous

Employees89
Market Cap$38.58 million
Next Earnings Date3/17/2020 (Estimated)
OptionableNot Optionable

Receive IDXG News and Ratings via Email

Sign-up to receive the latest news and ratings for IDXG and its competitors with MarketBeat's FREE daily newsletter.


Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions

What is Interpace Diagnostics Group's stock symbol?

Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."

How were Interpace Diagnostics Group's earnings last quarter?

Interpace Diagnostics Group Inc (NASDAQ:IDXG) announced its quarterly earnings results on Wednesday, November, 13th. The business services provider reported ($0.19) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.00. The business services provider had revenue of $7.73 million for the quarter, compared to analyst estimates of $10 million. Interpace Diagnostics Group had a negative net margin of 77.55% and a negative return on equity of 58.48%. View Interpace Diagnostics Group's Earnings History.

When is Interpace Diagnostics Group's next earnings date?

Interpace Diagnostics Group is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Interpace Diagnostics Group.

What price target have analysts set for IDXG?

3 brokers have issued 12-month price objectives for Interpace Diagnostics Group's shares. Their forecasts range from $2.00 to $15.00. On average, they anticipate Interpace Diagnostics Group's share price to reach $6.67 in the next year. This suggests that the stock has a possible downside of 34.0%. View Analyst Price Targets for Interpace Diagnostics Group.

What is the consensus analysts' recommendation for Interpace Diagnostics Group?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Interpace Diagnostics Group.

Has Interpace Diagnostics Group been receiving favorable news coverage?

News headlines about IDXG stock have trended neutral recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a coverage optimism score of 0.4 on InfoTrie's scale. They also assigned news articles about the business services provider a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Interpace Diagnostics Group.

Are investors shorting Interpace Diagnostics Group?

Interpace Diagnostics Group saw a drop in short interest in the month of January. As of January 31st, there was short interest totalling 137,700 shares, a drop of 90.8% from the January 15th total of 1,500,000 shares. Based on an average daily trading volume, of 51,200 shares, the short-interest ratio is currently 2.7 days. Approximately 4.3% of the company's shares are sold short. View Interpace Diagnostics Group's Current Options Chain.

Who are some of Interpace Diagnostics Group's key competitors?

What other stocks do shareholders of Interpace Diagnostics Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Diagnostics Group investors own include Histogenics (HSGX), Novavax (NVAX), AVEO Pharmaceuticals (AVEO), Magnegas Applied Tchnlgy Sltns (MNGA), SCYNEXIS (SCYX), Advanced Micro Devices (AMD), Genocea Biosciences (GNCA), Trevena (TRVN), Netflix (NFLX) and Verastem (VSTM).

Who are Interpace Diagnostics Group's key executives?

Interpace Diagnostics Group's management team includes the folowing people:
  • Mr. Jack E. Stover, CEO, Pres & Director (Age 66)
  • Mr. James E. Early, CFO, Sec. & Treasurer (Age 65)
  • Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 52)
  • Mr. Glenn Gershon, Sr. VP of Operations
  • Mr. Thomas John Freeburg, Chief Accounting Officer (Age 51)

Who are Interpace Diagnostics Group's major shareholders?

Interpace Diagnostics Group's stock is owned by many different of retail and institutional investors. Top institutional investors include Perkins Capital Management Inc. (60.10%), Essex Investment Management Co. LLC (17.52%), Virtu Financial LLC (2.26%), Cambridge Investment Research Advisors Inc. (1.44%) and UBS Group AG (0.48%). View Institutional Ownership Trends for Interpace Diagnostics Group.

Which institutional investors are selling Interpace Diagnostics Group stock?

IDXG stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View Insider Buying and Selling for Interpace Diagnostics Group.

Which institutional investors are buying Interpace Diagnostics Group stock?

IDXG stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Essex Investment Management Co. LLC, UBS Group AG and Cambridge Investment Research Advisors Inc.. View Insider Buying and Selling for Interpace Diagnostics Group.

How do I buy shares of Interpace Diagnostics Group?

Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Interpace Diagnostics Group's stock price today?

One share of IDXG stock can currently be purchased for approximately $10.10.

How big of a company is Interpace Diagnostics Group?

Interpace Diagnostics Group has a market capitalization of $38.58 million and generates $21.90 million in revenue each year. The business services provider earns $-12,190,000.00 in net income (profit) each year or ($4.30) on an earnings per share basis. Interpace Diagnostics Group employs 89 workers across the globe.View Additional Information About Interpace Diagnostics Group.

What is Interpace Diagnostics Group's official website?

The official website for Interpace Diagnostics Group is http://www.interpacediagnostics.com/.

How can I contact Interpace Diagnostics Group?

Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]


MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  282 (Vote Outperform)
Underperform Votes:  205 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/25/2020 by MarketBeat.com Staff

Featured Article: What is a capital gain?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel